Eli Lilly has stated it "remains confident in the differentiated benefits of tirzepatide." Facing generic competition, Novo Nordisk has taken several steps: Launch of rebranded versions In December 2025, Health Canada approved two Novo Nordisk rebranded versions on December 22: These are identical to the branded versions but come in different packaging
Because retatrutide is investigational, the question of who should use it cannot be answered clinically
Eligibility is determined by a healthcare professional after reviewing medical history, current medications, and potential risk factors
Pregnancy and breastfeeding are clear contraindications - we lack sufficient safety data on high-dose IV administration during these times
Obese people aren't just shamed for how they look - they're at a legitimately higher risk for long-term health problems
Yes, combining GLP-1 therapy with nutrition, exercise, and sleep strategies produces the strongest results